Navigation Links
Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
Date:1/12/2009

NEW YORK, Jan. 12 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. has completed a dual listing. The Company's shares are now listed on the Frankfurt Borse (symbol PBO) in addition to the OTC BB (OTC Bulletin Board: PLMO).

"The dual listing will play an important role in the future development and financing of the Company, bringing a substantial opportunity to investors outside of the United States and Canada" - Garry McCann, CEO Pulmo BioTech Inc.

Pulmo BioTech's operational subsidiary, PulmoScience, is planning Phase II Human Trials for its PulmoBind product candidate for the Molecular Imaging of the vascular system of the lungs, which will follow the successful completion of its Phase I trials. The company intends to carry out European Phase II trials in parallel with similar trials in the USA and Canada. The resulting increased visibility in Europe will further raise the profile of the company.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Pulmo BioTech's mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stock holders.

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind.

The company was conceived within the Montreal Heart Institute "MHI" (a world renowned hospital and educational facility). Jointly owned by MHI's subsidiary, Innovacor, as the technical and operational partner, Dr. Jocelyn Dupuis (the scientific director and originator of the PulmoBind Molecular Imaging technology), and by Pulmo BioTech Inc. as the funding partner, PulmoScience Inc. aims to develop this unique and exciting technology, to fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worth in excess of $500 million per annum and that, provided Regulatory Approval is achieved, the safety and efficacy of its products could allow it to dominate that market.

About PulmoBind

PulmoBind uses an intravenously delivered radionuclide tagged molecule which specifically bonds to the inner walls of the circulatory system in the lungs, and, by the use of an external Gamma Camera, allows an image of the integrity of the blood vessels throughout the lungs to be seen by a diagnostic clinician. PulmoScience is currently undertaking Regulatory Approval for Phase I Human Trials, and while subsequent results from additional tests might not corroborate the current results, PulmoScience believes that PulmoBind has the potential to dominate the market for the diagnosis of Pulmonary Embolism. In particular, this belief is driven by PulmoScience's expectations of the improved safety and efficacy that PulmoBind will offer when compared to the current incumbent nuclear medicine based technology for the diagnosis of Pulmonary Embolism. In addition, early indications are that PulmoBind could be highly effective in the early stage diagnosis of Pulmonary Hypertension, a condition for which there is no current front line diagnostic test. The addressable market for the product candidates being developed by PulmoScience is believed by the company to be worth in excess of $500 million per annum.

Forward-Looking Statements

Forward-looking statements contained in this and other written and oral reports are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. All statements regarding future performance, earnings projections, regulatory approval, events or developments are forward-looking statements. It is possible that the future performance of the company may differ materially from current expectations, depending on economic conditions and the uncertainty of regulatory approval. A change in economic conditions may have a particularly volatile effect on results. Among the other factors which may affect future performance are: competitive market conditions and resulting effects on sales and pricing; increases in raw-material costs that cannot be recovered in product pricing; and global economic factors, including difficulties entering new markets and general economic conditions such as inflation, interest rates and credit availability. The company makes these statements as of the date of this disclosure, and undertakes no obligation to update them.


'/>"/>
SOURCE Pulmo BioTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
2. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
3. Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease
4. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
7. Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
8. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
9. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
10. Positive Mid-Term Results on CryoValve(R) SG Pulmonary Human Heart Valve Presented at Western Thoracic Meeting
11. Pulmo BioTech Inc. Completes Bio-Distribution Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... HARROGATE, England , February 5, 2016 ... --> Today, VoicePower Ltd - The Speech Recognition People, ... has been deployed to improve patient care, reduce turnaround times and ... ,- Wirral CCG ,- VoicePower client since 2013 Challenge: ... Challenge: --> - Six doctors ,- Wirral ...
(Date:2/4/2016)...  Edwards Lifesciences Corporation (NYSE: EW ), the ... and critical care monitoring, announced today that it has ... Morgan Stanley & Co. LLC to repurchase $325 million ... the Company,s previously authorized program to repurchase up to ... --> --> Under the ...
(Date:2/4/2016)... FOSTER CITY, Calif. , Feb. 4, 2016 ... (the "Company") today announced it has entered into ... and Exchange Commission (SEC) fully resolving the SEC,s ... Practices Act (FCPA).  Under the terms of the ... total of $12.8 million, including disgorgement, pre-judgment interest ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... Freed-Hardeman University President Joe A. Wiley ... joint enrollment and degree completion agreement. The agreement, which begins with the ... FHU|Dickson. , The agreement allows students to be jointly admitted to both ...
(Date:2/5/2016)... ... 05, 2016 , ... The American public tends to feel uncomfortable about drinking ... regular municipal or well water. The recent experience with lead contaminated water in Flint, ... long way toward increasing public acceptance of recycled waste water as drinking water. ...
(Date:2/5/2016)... ... , ... At its annual meeting held last week, the American Parkinson Disease ... of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are pleased ... APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he was ...
(Date:2/5/2016)... IL (PRWEB) , ... February 05, 2016 , ... In ... disguised form as a dream. A hallmark feature of patients with eating disorders is ... needs. The eating disorder behaviors and obsessions are regarded as maladaptive means for coping ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( http://www.kicventures.com ... Development event in New York City on Thursday, January 21, 2016. Kingsley ... Mediacom, (both alumnus of the varsity Columbia soccer program) spoke at the event, ...
Breaking Medicine News(10 mins):